General Discussions

A New Tumor Marker for Pancreatic Cancer?

By LISA SCHULMEISTER, RN, MN, APRN-BC, FAAN
PUBLISHED THURSDAY, JANUARY 1, 1970
Pancreatic cancer often is diagnosed at a later stage of disease. Ideally, identification of a tumor marker or other early detection technique would reduce deaths from pancreatic cancer.

Researchers at the Mayo Clinic and University of Pennsylvania identified secreted proteins and tested a subset of these proteins to determine if they might be markers of pancreatic ductal adenocarcinoma (PDAC). In a phase I study, a phase 2a validation study, and a second phase 2b study (746 blood samples in total), concentrations of plasma thrombospondin-2 (THBS2) were able to discriminate resectable stage I cancer as readily as stage III and IV pancreatic tumors. THBS2 plasma concentrations combined with those for CA 19-9 increased the ability to distinguish PDAC from pancreatitis, and may improve the early detection of PDAC.

The study findings are available at here.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.